Advanced

Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination

Gefenaite, Giedre LU ; Tacken, Margot ; Bos, Jens ; Stirbu-Wagner, Irina ; Korevaar, Joke C. ; Stolk, Ronald P. ; Wolters, Bert ; Bijl, Marc ; Postma, Maarten J. and Wilschut, Jan , et al. (2013) In PLoS ONE 8(6).
Abstract

Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza... (More)

Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.Conclusions:Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
in
PLoS ONE
volume
8
issue
6
article number
e66125
publisher
Public Library of Science
external identifiers
  • scopus:84879269590
  • pmid:23840413
ISSN
1932-6203
DOI
10.1371/journal.pone.0066125
language
English
LU publication?
no
id
d4c7107d-465c-405f-8ee6-0710dd5b69b6
date added to LUP
2020-05-14 14:24:47
date last changed
2021-01-06 01:10:26
@article{d4c7107d-465c-405f-8ee6-0710dd5b69b6,
  abstract     = {<p>Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n&gt;25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.Conclusions:Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.</p>},
  author       = {Gefenaite, Giedre and Tacken, Margot and Bos, Jens and Stirbu-Wagner, Irina and Korevaar, Joke C. and Stolk, Ronald P. and Wolters, Bert and Bijl, Marc and Postma, Maarten J. and Wilschut, Jan and Nichol, Kristin L. and Hak, Eelko},
  issn         = {1932-6203},
  language     = {eng},
  number       = {6},
  publisher    = {Public Library of Science},
  series       = {PLoS ONE},
  title        = {Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination},
  url          = {http://dx.doi.org/10.1371/journal.pone.0066125},
  doi          = {10.1371/journal.pone.0066125},
  volume       = {8},
  year         = {2013},
}